Cellulitis News and Research

Latest Cellulitis News and Research

Many pediatric respiratory hospitalizations unnecessary

Study findings suggest that a large number of pediatric hospitalizations, particularly those of a respiratory nature, could be prevented.

11 Sep 2012

EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

Pfizer Inc. announced today that the European Commission (EC) has granted marketing authorization for INLYTA (axitinib) for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of kidney cancer, after failure of prior treatment with sunitinib or a cytokine.

4 Sep 2012

Combination therapy does not change safety and efficacy relationship of TORISEL for advanced RCC

Pfizer Inc. announced that the Phase 3 INTORACT trial (B1771006), evaluating the combination of bevacizumab plus TORISEL (temsirolimus) compared with bevacizumab plus interferon-alfa-2a (IFN-α-2a) in the first-line treatment of patients with advanced renal cell carcinoma (RCC) across risk groups, did not meet its primary endpoint of superiority in extending progression free survival (PFS) in the study population.

12 Aug 2012

Skin cell spray key to venous leg ulcer treatment

A spray consisting of a mixture of keratinocyte and fibroblast skin cells holds promise for treatment of venous leg ulcers, show results from a phase II randomized controlled trial published in The Lancet.

3 Aug 2012

Healthpoint Biotherapeutics announces results from HP802-247 Phase 2b trial on venous leg ulcers

Healthpoint Biotherapeutics today announced that the results for its Phase 2b clinical trial investigating the efficacy of HP802-247 in venous leg ulcers is published on The Lancet, beginning August 3, 2012, with Online First access to the article, followed by print publication in the next issue.

3 Aug 2012

Patients with history of skin infection more likely to develop surgical site infections

Johns Hopkins scientists have engineered cells that behave like AND and OR Boolean logic gates, producing an output based on one or more unique inputs. This feat, published in the May issue of Nature Chemical Biology, could eventually help researchers create computers that use cells as tiny circuits.

30 May 2012

Pfizer fails to meet primary endpoint in TORISEL Phase 3 study for advanced RCC

Pfizer Inc announced that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL(temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib.

16 May 2012

Study describes first known case of necrotizing fasciitis from bath salts

A study led by Russell R. Russo, MD, a third-year Orthopaedic Surgery resident at LSU Health Sciences Center New Orleans School of Medicine, has identified a new source of life-threatening necrotizing fasciitis - "bath salts."

13 Jan 2012

TNF inhibitors may minimally increase risk of serious infections

Biologic drugs have revolutionized treatment of autoimmune diseases during the past decade despite belief there is an increased risk for serious infections from using them. But new research from the University of Alabama at Birmingham Center for Education and Research on Therapeutics reveals that a class of biologics called tumor necrosis factor antagonists, or TNF inhibitors, may only minimally increase risk compared to more traditional therapies.

17 Nov 2011

Human Genome Sciences to present abstracts regarding BENLYSTA, SLE at ACR/ARHP meeting

Human Genome Sciences, Inc. announced today that several abstracts related to BENLYSTA (belimumab) and systemic lupus erythematosus will be presented at the annual meeting of the American College of Rheumatology/ Association of Rheumatology Health Professionals, being held in Chicago, IL from November 4 to November 9, 2011.

5 Nov 2011

Amgen to present data from several Prolia studies at ASBMR 2011 meeting

Amgen today announced that it will present data from several Prolia (denosumab) studies, including eight year efficacy and safety data from a Phase 2 extension study in women with postmenopausal osteoporosis with low bone mineral density (BMD), at the 2011 American Society for Bone and Mineral Research (ASBMR) Annual Meeting in San Diego, Calif. from Sept. 16-20, 2011.

19 Aug 2011

Novartis Afinitor Phase III trial on tuberous sclerosis meets primary endpoint

Novartis Pharmaceuticals Corporation announced today Phase III trial results that showed more than one-third of patients taking Afinitor tablets experienced a 50% or greater reduction in the size of their subependymal giant cell astrocytomas, non-cancerous brain tumors associated with tuberous sclerosis complex.

8 Jul 2011

Medical management preferred over surgery for pediatric orbital cellulitis

Researchers from Hasbro Children's Hospital in Providence, R.I., report that medical management may be preferred over surgery for children with orbital cellulitis, an acute infection of the tissues surrounding the eye. They have determined the criteria for surgical intervention should be dependent upon the size of a subperiosteal abscess (SPA).

9 Jun 2011

Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011

In data presented at The American Society of Clinical Oncology (ASCO) Annual Meeting, cancer researchers found that the brain tumor vaccine HSPPC-96 for treating recurrent gliobastoma (GBM) has a favorable safety profile and extends survival by two to three times more than the current median survival rate.

4 Jun 2011

New GARDASIL data against Human Papillomavirus presented at EUROGIN conference

A real-world study evaluating the safety of GARDASIL among 189,629 females in California found no serious adverse events related to vaccination, no safety signals for any health event resulting in an emergency room visit or hospitalization and no safety signals associated with pre-specified autoimmune conditions or pregnancy outcomes.

9 May 2011

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

The Government of Rwanda, together with QIAGEN N.V. and Merck, known as MSD outside the United States and Canada, today announced the launch, in Kigali, Rwanda, of a comprehensive national cervical cancer prevention program that includes vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls 12 to 15 years of age and modern molecular diagnostic screening for women between the ages of 35 and 45.

From QIAGEN Manchester Limited 25 Apr 2011

Positive results from Nabriva's BC-3781 Phase II trial in ABSSSI

Nabriva Therapeutics today announced the successful results of a Phase II clinical trial of BC-3781 in acute bacterial skin and skin structure infections.

18 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

Amgen today announced new data that showed postmenopausal women with osteoporosis had significantly greater adherence, compliance, and persistence during Prolia® (denosumab) treatment than during alendronate treatment, an oral bisphosphonate commonly used to treat osteoporosis.

24 Mar 2011

FDA approves BENLYSTA for active, autoantibody-positive systemic lupus erythematosus

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced that the U.S. Food and Drug Administration has approved BENLYSTA® (belimumab) for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy.

10 Mar 2011

Cellulitis News and Research

Latest Cellulitis News and Research

Many pediatric respiratory hospitalizations unnecessary

EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

Combination therapy does not change safety and efficacy relationship of TORISEL for advanced RCC

Skin cell spray key to venous leg ulcer treatment

Healthpoint Biotherapeutics announces results from HP802-247 Phase 2b trial on venous leg ulcers

Patients with history of skin infection more likely to develop surgical site infections

Pfizer fails to meet primary endpoint in TORISEL Phase 3 study for advanced RCC

Study describes first known case of necrotizing fasciitis from bath salts

TNF inhibitors may minimally increase risk of serious infections

Human Genome Sciences to present abstracts regarding BENLYSTA, SLE at ACR/ARHP meeting

Amgen to present data from several Prolia studies at ASBMR 2011 meeting

Novartis Afinitor Phase III trial on tuberous sclerosis meets primary endpoint

Medical management preferred over surgery for pediatric orbital cellulitis

Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011

New GARDASIL data against Human Papillomavirus presented at EUROGIN conference

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

Positive results from Nabriva's BC-3781 Phase II trial in ABSSSI

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

FDA approves BENLYSTA for active, autoantibody-positive systemic lupus erythematosus

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Cellulitis News and Research

Latest Cellulitis News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in